JP2023506750A5 - - Google Patents
Info
- Publication number
- JP2023506750A5 JP2023506750A5 JP2022535429A JP2022535429A JP2023506750A5 JP 2023506750 A5 JP2023506750 A5 JP 2023506750A5 JP 2022535429 A JP2022535429 A JP 2022535429A JP 2022535429 A JP2022535429 A JP 2022535429A JP 2023506750 A5 JP2023506750 A5 JP 2023506750A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025064328A JP2025111508A (ja) | 2019-12-11 | 2025-04-09 | Ｌｔｂｒ及びｅｄｂ結合ドメインを含む多重特異性結合分子並びにその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962946452P | 2019-12-11 | 2019-12-11 | |
| US62/946,452 | 2019-12-11 | ||
| PCT/EP2020/085623 WO2021116337A1 (en) | 2019-12-11 | 2020-12-10 | Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025064328A Division JP2025111508A (ja) | 2019-12-11 | 2025-04-09 | Ｌｔｂｒ及びｅｄｂ結合ドメインを含む多重特異性結合分子並びにその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023506750A JP2023506750A (ja) | 2023-02-20 |
| JP2023506750A5 true JP2023506750A5 (https=) | 2023-11-20 |
| JP7837867B2 JP7837867B2 (ja) | 2026-03-31 |
Family
ID=74104042
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022535429A Active JP7837867B2 (ja) | 2019-12-11 | 2020-12-10 | Ｌｔｂｒ及びｅｄｂ結合ドメインを含む多重特異性結合分子並びにその使用 |
| JP2025064328A Pending JP2025111508A (ja) | 2019-12-11 | 2025-04-09 | Ｌｔｂｒ及びｅｄｂ結合ドメインを含む多重特異性結合分子並びにその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025064328A Pending JP2025111508A (ja) | 2019-12-11 | 2025-04-09 | Ｌｔｂｒ及びｅｄｂ結合ドメインを含む多重特異性結合分子並びにその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20210188990A1 (https=) |
| EP (1) | EP4073111A1 (https=) |
| JP (2) | JP7837867B2 (https=) |
| KR (1) | KR20220130687A (https=) |
| CN (1) | CN115087670B (https=) |
| AU (1) | AU2020401755A1 (https=) |
| CA (1) | CA3164226A1 (https=) |
| IL (1) | IL293742A (https=) |
| WO (1) | WO2021116337A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115677851B (zh) * | 2021-07-29 | 2024-03-22 | 东莞市朋志生物科技有限公司 | 一种免疫阻断抗体或其抗原结合片段及其应用 |
| CR20240246A (es) * | 2021-12-20 | 2024-07-19 | Hoffmann La Roche | Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden |
| US20250235534A1 (en) * | 2022-04-13 | 2025-07-24 | Vib Vzw | An LTBR Agonist In Combination Therapy Against Cancer |
| IL318055A (en) | 2022-07-08 | 2025-02-01 | Viromissile Inc | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF |
| KR20260036556A (ko) | 2023-07-07 | 2026-03-17 | 메스태그 테라퓨틱스 리미티드 | 결합 작제물 |
| EP4527851A1 (en) | 2023-09-22 | 2025-03-26 | Bayer Aktiengesellschaft | Bispecific antibodies binding ltbr and lrrc15 |
| WO2025172588A1 (en) | 2024-02-16 | 2025-08-21 | Mestag Therapeutics Ltd | Bispecific constructs directed against fap and ltbr |
| WO2025172587A1 (en) | 2024-02-16 | 2025-08-21 | Mestag Therapeutics Ltd | Binding constructs |
| WO2025221728A2 (en) * | 2024-04-15 | 2025-10-23 | Janssen Biotech, Inc. | Ltbr binding molecules and uses thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9610967D0 (en) | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
| JP2003524018A (ja) * | 2000-02-24 | 2003-08-12 | アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ | フィブロネクチンのｅｄ‐ｂドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用 |
| PL366307A1 (en) | 2000-10-13 | 2005-01-24 | Biogen, Inc. | Humanized anti-lt-beta-r antibodies |
| CA2491480A1 (en) | 2002-07-01 | 2004-01-08 | Biogen, Inc. | Humanized anti-lymphotoxin beta receptor antibodies |
| CA2511013A1 (en) * | 2002-12-20 | 2004-07-15 | Biogen Idec Ma Inc. | Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof |
| WO2004058183A2 (en) * | 2002-12-20 | 2004-07-15 | Biogen Idec Ma Inc. | Lymphotoxin beta receptor agents in combination with chemotherapeutic agents |
| KR20060132006A (ko) * | 2004-03-23 | 2006-12-20 | 비오겐 아이덱 엠에이 아이엔씨. | 수용체 커플링제 및 이의 치료적 용도 |
| WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| WO2006074399A2 (en) * | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー／エス | 二重特異性抗体の生産 |
| EP1892248A1 (en) | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| MX2012002428A (es) | 2009-08-27 | 2012-09-12 | Covagen Ag | Compuestos de union il-17 y usos medicos de los mismos. |
| HRP20241208T1 (hr) | 2010-04-20 | 2024-11-22 | Genmab A/S | Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju |
| ES2758994T3 (es) | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| BR112014010580B1 (pt) | 2011-11-04 | 2021-01-12 | Zymeworks, Inc. | constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado |
| EP2638916A1 (en) * | 2012-03-16 | 2013-09-18 | Covagen AG | Novel binding molecules with antitumoral activity |
| JP6325463B2 (ja) | 2012-03-16 | 2018-05-16 | コヴァジェン アクチェン ゲゼルシャフト | 抗腫瘍活性を有する新規結合分子 |
| WO2014170063A1 (en) | 2013-04-19 | 2014-10-23 | Covagen Ag | Novel bispecific binding molecules with antitumoral activity |
| US20170335281A1 (en) * | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| EP3341410B1 (en) * | 2015-08-24 | 2021-06-02 | Cellectis | Chimeric antigen receptors with integrated controllable functions |
| WO2018119118A1 (en) | 2016-12-20 | 2018-06-28 | Oncomed Pharmaceuticals, Inc. | Lymphotoxin-beta receptor-binding agents, targeting antibodies, and uses thereof |
| US20190100587A1 (en) | 2017-10-02 | 2019-04-04 | Covagen Ag | IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS |
| CN114258400A (zh) * | 2019-08-15 | 2022-03-29 | 詹森生物科技公司 | 用于改进的单链可变片段的材料和方法 |
-
2020
- 2020-12-10 CA CA3164226A patent/CA3164226A1/en active Pending
- 2020-12-10 WO PCT/EP2020/085623 patent/WO2021116337A1/en not_active Ceased
- 2020-12-10 EP EP20830098.8A patent/EP4073111A1/en active Pending
- 2020-12-10 JP JP2022535429A patent/JP7837867B2/ja active Active
- 2020-12-10 US US17/117,304 patent/US20210188990A1/en not_active Abandoned
- 2020-12-10 IL IL293742A patent/IL293742A/en unknown
- 2020-12-10 CN CN202080096332.8A patent/CN115087670B/zh active Active
- 2020-12-10 KR KR1020227023655A patent/KR20220130687A/ko active Pending
- 2020-12-10 AU AU2020401755A patent/AU2020401755A1/en active Pending
-
2024
- 2024-12-06 US US18/971,955 patent/US20250101123A1/en active Pending
-
2025
- 2025-04-09 JP JP2025064328A patent/JP2025111508A/ja active Pending